jcm-logo

Journal Browser

Journal Browser

Recent Advances in Clinical Pharmacology Based on Pharmacokinetics

A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 25 August 2026 | Viewed by 1858

Special Issue Editors


E-Mail Website
Guest Editor
Department of Pharmacology, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
Interests: clinical pharmacology; hypertension; cardiovascular diseases; lipid metabolism; nutrition
Special Issues, Collections and Topics in MDPI journals

E-Mail Website
Guest Editor
Department of Medical Sciences II—Pharmacology, Clinical Pharmacology and Algesiology, ”Grigore T. Popa” University of Medicine and Pharmacy, 700115 lași, Romania
Interests: arterial stiffness; adherence; antibiotics; stress hormones; clinical pharmacology; experimental pharmacology
Special Issues, Collections and Topics in MDPI journals
Department of Morphofunctional Sciences II—Biochemistry, Faculty of Medicine, “Grigore T. Popa” University of Medicine and Pharmacy, 700115 Iasi, Romania
Interests: endothelial dysfunction mechanisms; cardiovascular diseases; oxidative stress; biomarkers; homocysteine; anticoagulants
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

This Special Issue, entitled “Recent Advances in Clinical Pharmacology Based on Pharmacokinetics”, is dedicated to elucidating the pivotal interplay between pharmacokinetic principles and their translation into clinical practice.

We invite submissions that highlight novel methodologies, innovative technologies, and significant advancements in pharmacokinetics that directly impact patient care. The scope of this Special Issue encompasses a broad range of topics, including, but not limited to, the integration of pharmacokinetic data into clinical decision-making tools for dose optimization (including therapeutic drug monitoring), and the development and validation of novel PK, PK/PD, and physiologically based pharmacokinetic (PBPK) modeling for predicting drug efficacy and safety.

We welcome the submission of original research articles, comprehensive reviews, and insightful perspectives that contribute to a deeper understanding of the role of pharmacokinetics in advancing clinical pharmacology practice and improving patient outcomes. The overarching aim is to showcase cutting-edge research and foster discussions on the future directions of pharmacokinetics in the context of personalized and precision medicine.

We look forward to receiving your contributions.

Dr. Magdalena Cuciureanu
Prof. Dr. Cristina Ghiciuc
Dr. Nina Filip
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • PK/PD modeling
  • dose optimization
  • clinical decision-making tools
  • therapeutic drug monitoring
  • personalized medicine

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Other

11 pages, 997 KB  
Systematic Review
Clinical Use of Bayesian Model-Informed Precision Dosing in Routine Practice: A Focused Systematic Review
by Wael A. Alghamdi
J. Clin. Med. 2026, 15(10), 3838; https://doi.org/10.3390/jcm15103838 - 15 May 2026
Viewed by 320
Abstract
Background: Bayesian model-informed precision dosing (MIPD) is increasingly used to individualize drug therapy; therefore, this review aimed to identify and characterize its implementation in routine clinical practice. Methods: A focused systematic review was conducted. Web of Science Core Collection and PubMed were searched [...] Read more.
Background: Bayesian model-informed precision dosing (MIPD) is increasingly used to individualize drug therapy; therefore, this review aimed to identify and characterize its implementation in routine clinical practice. Methods: A focused systematic review was conducted. Web of Science Core Collection and PubMed were searched from inception to February 2026. Eligible studies were original research articles evaluating Bayesian MIPD in routine clinical practice using software platforms that supported dosing decisions. Data were synthesized descriptively. No formal risk-of-bias assessment was performed due to heterogeneity in study design. Results: Fifteen studies met the inclusion criteria. Anti-infective therapy predominated, particularly vancomycin (n = 11), with additional studies involving busulfan, mycophenolate mofetil, amikacin, and tobramycin. Commonly reported software platforms included InsightRx (n = 6) and DoseMeRx (n = 4), along with Abbottbase, NextDose, and ISBA. MIPD was mainly applied with therapeutic drug monitoring, reflecting predominant a posteriori use in routine care. Across studies, implementation was associated with improved pharmacokinetic target attainment, while a subset reported clinical benefits, including reduced nephrotoxicity and favorable effectiveness-related outcomes. Pharmacist involvement was commonly described. Conclusions: Published evidence indicates that Bayesian MIPD is being implemented in routine clinical settings, but current published experience is dominated by vancomycin-focused studies. Although the evidence base remains limited, it has grown since 2020 and suggests that software-supported Bayesian dosing can improve pharmacokinetic target attainment and may support better clinical outcomes. Full article
(This article belongs to the Special Issue Recent Advances in Clinical Pharmacology Based on Pharmacokinetics)
Show Figures

Figure 1

Back to TopTop